Anteris Technologies Global Corp. — Capital/Financing Update 2007

Sep 9, 2007

ASX ANNOUNCEMENT

(ASX:BOD)

==> picture [142 x 70] intentionally omitted <==

10 September 2007

POSITIVE RESULTS FROM A 12 MONTH COMPARATIVE PATCH STUDY

Key points:

• bioMD Limited, via its subsidiary company, Celxcel, reports continued positive pre-clinical results for its ADAPT[®] Advanced Tissue Process in producing a durable biomaterial patch.

• This comparative study of two commercially available biomaterial patches and an ADAPT[®] treated biomaterial patch was conducted over an extended implantation time of 12 months, and confirmed that the ADAPT[®] Process produces a more durable and regenerative biomaterial.

• The global market for Soft Tissue Repair exceeds AU$1 billion and is considered a major marketing opportunity for bioMD.

bioMD Limited (ASX: BOD), announces positive histology results from a Western Australian, preclinical, small animal trial of tissue engineered ADAPT® treated bovine pericardial patches. These were compared with two commercially available patch materials in a subcutaneous (under the skin) rat model.

This study is an extension of the comparative patch study conducted over 200 days - the results of which were announced on 14 March 2007. A number of juvenile Wistar rats from that study were left implanted with patches of each biomaterial until they reached the 12 month milestone.

bioMD ’s Managing Director, Michael Bennett, said:

“The histology results of each of the explanted patches clearly indicate the ADAPT® treated biomaterial patch was undergoing controlled andipogenesis and remodeling whilst the commercially available products were already being compromised by recognised detrimental factors, such as fibrosis and calcification, that inhibit durability and regeneration.”

The histology results can be summarised as follows:

ADAPT ® Tissue Engineered Patch:

Histology of the ADAPT® treated pericardial patches showed long term structural integrity and flexibility with signs of active adipogenesis as a form of remodeling on the edge of the matrix – more detail magnification shows revascularization and new collagen being laid down in certain areas of the matrix.

bioMD Limited ABN 35 088 221 078 PO Box 7209 Cloisters Square WA 6850 • Tel +61 8 9262 6777 • Fax +61 8 9322 3433 E-mail: info@biomd.com.au • Web Site: www.biomd.com.au

ASX ANNOUNCEMENT

(ASX:BOD)

==> picture [142 x 70] intentionally omitted <==

Commercially Available Patch A:

Histology revealed Patch A is showing early signs of remodeling in the form of active adipogenesis. Some encapsulation was noted.

Commercially Available Patch B:

Histology revealed uneven remodeling with a total breakdown of approximately 50% of the original matrix and severe calcification in certain areas. Empty spaces created by the broken down matrix are filled with a mixture of fibrous connective tissue and adipose cells. Remaining part of the matrix is encapsulated by a dense layer of fibrous tissue.

ADAPT® treated cardiovascular tissue patches will be used in an ethics approved Phase II Human Clinical Trial at the Universitas Hospital in Bloemfontein, South Africa.

The ADAPT® Advanced Tissue Process was developed by Celxcel, a tissue engineering company and a subsidiary of bioMD Limited. bioMD aims to develop the process to a stage where it can capture part of a global Soft Tissue Repair market currently worth in excess of AU$1 billion a year. Bioimplant patch materials are used for the surgical reconstruction of diseased and/or damaged human tissues, including valve leaflets on replacement stented tissue heart valves, patching of damaged heart structures and in reconstruction and repair of the abdomen and pelvic floor.

For further information:

Michael Bennett Managing Director +61 8 9262 6777 or 0419 944 567

About bioMD Limited (BOD)

bioMD Limited (BOD), based in Perth, Western Australia and listed on the Australian Stock Exchange, was established in 2003 to research, develop and commercialise new, cost effective and innovative medical devices and technologies. The company is currently focusing on three projects, the ADAPT[®] Advanced Tissue Process (through its subsidiary Celxcel Pty Ltd), the collaborative research project with CSIRO to develop a new material for use in the manufacture of intravenous (IV) catheters and Vascular Access Devices, and the development of a pre-filled safety syringe.